返回 
加入收藏
氟伏沙明联合阿立哌唑治疗强迫症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 氟伏沙明联合阿立哌唑治疗强迫症的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察氟伏沙明联合阿立哌唑治疗强迫症的的疗效和安全性。方法：140例强迫症患者随机分为对照组（70例）和观察组（70例）。两组患者均给予无抽搐性电休克治疗，每周2～3次；在此基础上，对照组患者给予马来酸氟伏沙明片，起始剂量50 mg，口服，每日1次，2周内根据病情改善与患者耐受情况逐渐加量至每日200～300 mg，分 2～3次服用；观察组患者在对照组治疗的基础上给予阿立哌唑片，起始剂量2.5 mg，口服，每日1次，3 d后加量至5 mg，每日1次，2周内根据病情改善与患者耐受情况逐渐加量至每日10～15 mg，分2～3次服用。两组疗程均为8周。观察两组患者的临床疗效，治疗前后耶鲁-布朗强迫症状量表（Y-BCOS）评分、汉密尔顿焦虑量表（HAMA）评分、生存质量综合评定问卷（GQOLI-74）评分及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者Y-BCOS评分、HAMA评分、GQOLI-74评分比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者Y-BCOS评分、HAMA评分均显著低于同组治疗前，且观察组显著低于对照组；两组患者GQOLI-74评分均显著高于同组治疗前，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，氟伏沙明联合阿立哌唑治疗强迫症的疗效显著优于单用氟伏沙明，可有效改善精神症状，提高生活质量，且不增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe the efficacy and safety of fluvoxamine combined with aripiprazole in the treatment of obsessive-compulsive disorder. METHODS： 140 patients with obsessive-compulsive disorder were randomly divided into control group （70 cases） and observation group （70 cases）. All patients received no convulsive electrical shock， 2-3 times a week； based on it， control group was orally given Fluvoxamine tablet with initial dose of 50 mg， once a day， then gradually increased to 200-300 mg/d within 2 weeks based on condition improvement and patients’ tolerance by 2-3 times； observation group was additionally given Aripiprazole tablet 2.5 mg， orally， once a day， and increased to 5 mg after 3 d， once a day， then gradually increased to 10-15 mg/d within 2 weeks based on condition improvement and patients’ tolerance by 2-3 times； all patients were treated for 8 weeks. Clinical efficacy， Yale-Brown obsessive-compulsive symptoms （Y-BCOS） score， Hamilton anxiety （HAMA） score， comprehensive quality of life questionnaire （GQOLI） -74 score before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， with statistical significance （P＜0.05）. Before treatment， there were no significant differences in the Y-BCOS score， HAMA score and GQOLI-74 score in 2 groups （P＞0.05）. After treatment， Y-BCOS score and HAMA score in 2 groups were significantly lower than before， and observation group was lower than control group， GQOLI-74 scores were significantly higher than before， and observation group was higher than control group， with statistical significances （P＜0.05）. And there was no significant difference in the incidence of adverse reactions （P＞0.05）. CONCLUSIONS： Based on conventional treatment， fluvoxamine combined with aripiprazole shows better efficacy than fluvoxamine alone in the treatment of obsessive-compulsive disorder， which can effectively improve mental symptoms and the quality of life， does not increase the incidence of adverse reactions. |
| 期刊： | 2017年第28卷第3期 |
| 作者： | 白月辉，梁希江 |
| AUTHORS： | BAI Yuehui，LIANG Xijiang |
| 关键字： | 氟伏沙明；阿立哌唑；强迫症；疗效；安全性；耶鲁-布郎强迫症状量表 |
| KEYWORDS： | Fluvoxamine； Aripiprazole； Obsessive-compulsive disorder； Efficacy； Safety；Yale-Brown obsessive-compulsive symptoms |
| 阅读数： | 4813 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
